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OBJECTIVE—Markers reliably identifying vascular damage and
risk in diabetic patients are rare, and reports on associations of
serum adiponectin with macrovascular disease have been incon-
sistent. In contrast to existing data on serum adiponectin, this
study assesses whether urinary adiponectin excretion might
represent a more consistent vascular damage marker in type 2
diabetes.
RESEARCH DESIGN AND METHODS—Adiponectin distribu-
tion in human kidney biopsies was assessed by immunohisto-
chemistry, and urinary adiponectin isoforms were characterized
by Western blot analysis. Total urinary adiponectin excretion
rate was measured in 156 patients with type 2 diabetes who had
a history of diabetic nephropathy and 40 healthy control subjects
using enzyme-linked immunosorbent assay. Atherosclerotic bur-
den was assessed by common carotid artery intima-media-
thickness (IMT).
RESULTS—A homogenous staining of adiponectin was found
on the endothelial surface of glomerular capillaries and intrare-
nal arterioles in nondiabetic kidneys, whereas staining was
decreased in diabetic nephropathy. Low-molecular adiponectin
isoforms (30–70 kDa) were detected in urine by Western blot
analysis. Urinary adiponectin was signiﬁcantly increased in type
2 diabetes (7.68  14.26 vs. control subjects: 2.91  3.85 g/g
creatinine, P  0.008). Among type 2 diabetic patients, adi-
ponectinuria was associated with IMT (r  0.479, P  0.001) and
proved to be a powerful independent predictor of IMT (
0.360, P  0.001) in multivariable regression analyses. In a risk
prediction model including variables of the UK Prospective
Diabetes Study coronary heart disease risk engine urinary adi-
ponectin, but not the albumin excretion rate, added signiﬁcant
value for the prediction of increased IMT (P  0.007).
CONCLUSIONS—Quantiﬁcation of urinary adiponectin excre-
tion appears to be an independent indicator of vascular damage
potentially identifying an increased risk for vascular events.
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C
ardiovascular disease (CVD) is the leading
cause of mortality in patients with type 2 diabe-
tes, and the identiﬁcation of individual risk
patterns is fundamental for the prevention and
treatment of CVD. However, risk stratiﬁcation in patients
with diabetes is still vague (1,2), and, consequently, num-
bers needed to treat for prevention of a single cardiovas-
cular event in clinical trials are 100–200 patients per year
(3–5).
Most of the recently described risk markers are meta-
bolic or inﬂammatory molecules that do not directly
indicate vascular damage. Therefore, these indirect mark-
ers show variations in risk prediction depending on the
metabolic status of the study group (6,7). This becomes
evident reviewing data on serum adiponectin; whereas
low-circulating adiponectin was signiﬁcantly associated
with increased primary CVD risk in apparently healthy
men (8), subsequent studies in high-risk populations, as
well as patients with prevalent coronary heart disease
(CHD), failed to conﬁrm this association (9,10). A reason
for this discrepancy between different groups of risk
patients could be a reverse causality, where silent or
apparent CVD might lead to compensatory rises in serum
adiponectin. Consistently, it was shown in type 2 diabetic
patients that adiponectin is lowest in the presence of
impaired glucose regulation and early diabetes, whereas
long diabetes duration is associated with a signiﬁcant
increase in circulating adiponectin (11).
Adiponectin is a 30-kDa adipocyte-derived vasoactive
peptide closely linked to components of the metabolic
syndrome (rev. in 12). It has anti-inﬂammatory and anti-
atherosclerotic properties on endothelial cells by decreas-
ing vascular inﬂammation, foam cell formation, and cell
adhesion, which all are involved in the initiation and
progression of vascular lesions (12). Recently, it was
reported that adiponectin has a distinct role for glomerular
homeostasis in an experimental model (13). Hence, adi-
ponectin could be present on human renal endothelium
and glomerular capillary stress in diabetes may promote
shedding of adiponectin from endothelial surfaces by
proteolytic cleavage, causing degradation of high-order
complexes of adiponectin and subsequent appearance of
the adiponectin monomer (28 kDa), dimer (56 kDa),
and trimer (68 kDa) in urine.
We hypothesized that adiponectin appears in urine
consequently reﬂecting early glomerular vascular damage
in type 2 diabetes rather than the metabolic changes
associated with serum adiponectin. To characterize a
possible diagnostic value of urinary adiponectin excretion,
patients with type 2 diabetes and early diabetic nephrop-
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DIABETES, VOL. 58, SEPTEMBER 2009 2093athy (i.e., a history of microalbuminuria) were studied, and
the atherosclerotic burden of these patients was assessed
by quantiﬁcation of common carotid artery intima-media-
thickness (IMT). Both urinary adiponectin and urinary
albumin excretion rate (AER) as an established marker of
micro- and macrovascular dysfunction in type 2 diabetes
were evaluated for the prediction of increased IMT in
comparative analyses.
RESEARCH DESIGN AND METHODS
Study population and data collection. Patients (156) with type 2 diabetes,
according to the American Diabetes Association (ADA) criteria (14), were
recruited from family practices being referred to the diabetes outpatient clinic
at the University Hospital Heidelberg for specialist treatment. For eligibility,
patients had to have a documented history of microalbuminuria in at least two
separate urine samples [albumin creatinine ratio (ACR) 30 mg/g creatinine
or AER 30 mg/24h]. Healthy control subjects (40) were recruited at the
outpatient clinic of the University Hospital Wuerzburg. In the latter, manifest
CVD and/or diabetes, fasting plasma glucose (FPG) level 7 mmol/l, acute or
chronic kidney disease, present microalbuminuria, history of hypertension
and/or lipid disorder, and intake of any regular medication was an exclusion
criterion. Detailed patient characteristics are shown in Table 1. In all
individuals, 24-h urine samples were collected on 3 consecutive days and the
mean of AER and of the creatinine clearance was taken for statistical
evaluation. All blood values, as well as ambulatory 24-h blood pressure values
(given as mean of 24 h), were taken on day 1. The study complied with the
Declaration of Helsinki, and all subjects gave written informed consent. The
study was approved by the ethics committees of the Universities of Heidelberg
and Wuerzburg.
Adiponectin immunohistochemistry in human kidneys. Immunohisto-
chemical analyses were performed in human kidney biopsies from type 2
diabetic patients (n  6) and tumor-distant kidney tissues from nondiabetic
patients after tumornephrectomy (n  6). Early diabetic nephropathy (n  3)
was classiﬁed as presenting with micro- or macroalbuminuria and calculated
glomerular ﬁltration rate 60 ml/min. Indication for kidney biopsy was based
on progressive increase in proteinuria 1 g/24 h in two subjects and progres-
sive increase in serum creatinine in one. Late diabetic nephropathy (n  3)
was classiﬁed by micro- or macroalbuminuria and calculated glomerular
ﬁltration rate 30 ml/min. Indication for kidney biopsy in these patients was
progressive nephrotic proteinuria. In nondiabetic control subjects, tumor-
distant kidney tissue was embedded in parafﬁn blocks and according histo-
logical samples were qualiﬁed to show normal kidney morphology by two
independent experts. Utilization of noncancerous regions of resected kidneys
distant from the tumor as control tissue has previously been reported (15,16).
None of these patients had an FPG level 7 mmol/l or present microalbumin-
uria. Immunohistochemical staining was performed on 3-m sections of
formaldehyde-ﬁxed and parafﬁn-embedded tissue using the avidin-biotin com-
plex method. Tissues were deparafﬁnized with xylene and rehydrated through
graded concentrations of ethanol. After rehydration, the sections were pre-
treated by microwave heating in citrate buffer (pH 6.0) for 20 min. The primary
antibody against adiponectin (Adiponectin/Acrp30 biotinylated afﬁnity puri-
ﬁed polyclonal antibody) was obtained from R&D Systems (Minneapolis, MN)
and used at a dilution of 1:25 for2ha troom temperature, followed by
incubation with horseradish peroxidase–labeled streptavidin (Vector Labora-
tories, Burlingame, CA) diluted 1:200 for 1 h. NovaRED (Vector) was applied
for visualization. Control subjects, omitting the ﬁrst antibody for each parafﬁn
block tested, were negative.
Detection and characterization of adiponectin multimers in urine by
Western blot. SDS-PAGE was performed after modiﬁcation of the protocol
as previously described (17). Urinary samples (16 l) were mixed with
SDS-sample buffer and then incubated at room temperature for 1 h. Urinary
proteins were separated by 10% SDS-PAGE, and transferred to a nitrocellulose
membrane. Membranes were blocked with Tris-buffered saline Tween-5%
skim milk and then incubated with a goat anti-human adiponectin polyclonal
antibody (1:200; R&D Systems, Wiesbaden, Germany) for1ha troom
temperature. After washing (three times for 5 min), membranes were incu-
bated with horseradish peroxidase–conjugated donkey anti-goat antibody
(1:3,200; Santa Cruz Biotechnology, Heidelberg, Germany) for1ha troom
temperature and then washed thoroughly (three times for 5 min). Signals were
visualized using lumi-light Western blotting substrate (Roche Diagnostics,
Mannheim, Germany) and the image was acquired by Kodak IS440CF Imaging
Station. Speciﬁcity of bands was shown in a competition experiment. In
TABLE 1
Characteristics of control and type 2 diabetic subjects and Spearman’s correlation coefﬁcients between serum or urinary adiponectin
levels and cardiovascular risk factors and measures of subclinical atherosclerosis in type 2 diabetic patients
Control
subjects
Type 2 diabetic
patients P*
Serum
adiponectin
Urinary
adiponectin
rP † rP †
n 40 156
Sex (male) 25 (61.0) 117 (75.0) 0.017 0.290 0.001 0.009 0.915
Age (years) 51.9  9.5 60.5  7.8 0.001 0.327 0.001 0.181 0.025
BMI (kg/m²) 25.4  4.6 33.1  5.9 0.001 0.041 0.613 0.098 0.231
WHR 0.87  0.09 1.02  0.08 0.001 0.286 0.001 0.062 0.453
HDL cholesterol (mmol/l) 1.52  0.42 1.17  0.35 0.001 0.413 0.001 0.018 0.826
LDL cholesterol (mmol/l) 3.12  0.72 2.66  0.92 0.001 0.137 0.106 0.013 0.877
Triglycerides (mmol/l)‡ 1.06 (0.80–1.71) 1.87 (1.19–2.86) 0.001 0.311 0.001 0.069 0.400
FPG (mmol/l) 5.06  0.6 8.03  2.74 0.001 0.167 0.041 0.073 0.375
A1C (%) 5.5  0.5 7.2  1.2 0.001 0.143 0.085 0.080 0.342
Creatinine clearance (ml/min) 119.3  41.2 109.6  40.7 0.146 0.223 0.011 0.156 0.074
Cystatin C (mg/l) 0.57  0.13 0.79  0.31 0.001 0.141 0.084 0.025 0.759
AER (mg/24h)‡ 10 43.9 (21.5–103.1) 0.001 0.009 0.911 0.031 0.707
High-sensitive CRP (mg/l)‡ 0.2 (0.1–0.6) 2.3 (1.0–4.9) 0.001 0.188 0.024 0.152 0.069
Systolic blood pressure, 24 h (mmHG) 124  14 140  16 0.001 0.025 0.770 0.124 0.137
Diastolic blood pressure, 24 h (mmHG) 76  98 0  8 0.010 0.093 0.265 0.031 0.715
Mean arterial pressure, 24 h (mmHG) 92  99 9  10 0.001 0.060 0.472 0.073 0.383
Duration of diabetes (years)‡ 11.0 (6.0–16.0) 0.135 0.099 0.211 0.009
Current smoker (yes) 13 (31.7) 25 (16.0) 0.027 0.054 0.509 0.022 0.788
Patient with angiotensin converting enzyme-inhibitor
or angiotensin receptor blocker (yes: n; %) 131 (84.0) 0.104 0.205 0.191 0.019
Patient with statins (yes: n; %) 91 (58.3) 0.074 0.364 0.016 0.846
Carotid IMT (mm) 0.88  0.15 0.202 0.017 0.479 0.001
Serum adiponectin (g/ml) 10.3  6.6 7.0  4.9 0.033 0.184 0.025
Urinary adiponectin (g/g creatinine) 2.91  3.85 7.68  14.26 0.008 0.184 0.025
Data are means  SD, n (%), or median (interquartile range). *P for type 2 diabetic versus control subjects (by independent t test for normally
distributed data or Mann-Whitney U test for not normally distributed data). †P by bivariate Spearman correlation analysis.
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g/ml recombinant human adiponectin (R&D Systems) as a competitor before
Western blotting.
Clinical chemistry. Blood was drawn on day 1 in a fasting state under
standardized conditions and stored at 80°C until analysis. Total urinary
adiponectin concentrations were measured in duplicates by a high-sensitive
enzyme-linked immunosorbent assay (ELISA; BioVendor, Brno, Czech Repub-
lic) according to the manufacturer’s protocol. The intra- and interassay
variations were 5.4 and 9.0%, respectively. Urinary adiponectin levels (nano-
gram per milliliter) were adjusted for urinary creatinine excretion and
expressed as micrograms per gram of creatinine for statistical analysis. In type
2 diabetic patients, presence of adiponectinuria was deﬁned as level mean 	
2 SD (95. percentile) of the adiponectin excretion rate in healthy control
subjects (3urinary adiponectin 10.61 g/g creatinine). FPG was measured
by a glucose oxidase method. Triglyceride, total cholesterol, and HDL
cholesterol levels were quantiﬁed by standard laboratory methods, and LDL
cholesterol levels were calculated by using the Friedewald formula. A1C was
measured by high-performance liquid chromatography on a Variant II device
(Bio-Rad Laboratories, Munich, Germany). Cystatin C was measured by ELISA
(BioVendor, Brno, Czech Republic), and high-sensitive C-reactive protein
(hsCRP) levels were determined by nephelometry (Dade Behring, Cupertino,
CA). AER was assessed and performed in three consecutive 24-h urinary
collections. For collection of the urine sample, a 3-l plastic container was
used, and the volume of urine was measured to the nearest 50 ml. Urine
aliquots were stored deep frozen at 80°C until analyses. Albumin levels were
determined by turbidimetry (Siemens Healthcare Diagnostics, Eschborn,
Germany). AER was expressed as milligrams per 24 h. Patients with an AER
of 30–300 mg/24 h were deﬁned to have microalbuminuria and an AER 300
mg/24 h was deﬁned as macroalbuminuria.
Assessment of carotid atherosclerosis. IMT was detected using high-
resolution B-mode ultrasound (Voluson 730 Kretz, Tiefenbach, Austria) of the
extracranial carotid arteries bilaterally under continuous detection of the
heart cycle using a three-lead electrocardiogram. The whole imaging and
quantiﬁcation procedure was performed digitally (Voluson 730 Kretz, Tiefen-
bach, Austria) at the time of study entry by a single investigator blinded for
clinical data. For the purpose of this study, IMTs of the far wall of the common
carotid artery were detected in end-diastolic frames, 10 mm proximal to the
carotid bulb, according to a previously described scanning protocol (18). The
measurements were performed in four points of both common carotid arteries
avoiding areas of atherosclerotic plaque formation. The mean of the resulting
eight single measurements was taken as mean IMT for statistical analyses in
this study.
Statistical analyses. Statistical analyses were performed using SPSS soft-
ware version 15.0 (SPSS, Chicago, IL). Spearman correlation coefﬁcients were
used to describe the association between urinary adiponectin and the vari-
ables of interest. Comparison between two sets of patients was performed by
independent t test or Mann-Whitney U test. Multivariable linear regression
analyses evaluated the association of urinary adiponectin with IMT. The
models ﬁtted for IMT as a dependent variable, included age, sex, waist-to-hip
ratio (WHR), HDL, LDL, hsCRP, A1C, AER, smoking status, mean arterial
pressure (MAP), diabetes duration, serum, and urinary adiponectin concen-
trations. The UK Prospective Diabetes Study (UKPDS) risk engine was
previously introduced as a parametric model that provides the estimates of
primary coronary heart disease (CHD) risk in type 2 diabetes (19). In contrast
to previous models for CHD, such as the Framingham risk equations, the
diabetes-speciﬁc approach of the UKPDS risk engine includes A1C as contin-
uous variable. Age as a risk factor is replaced by two diabetes-speciﬁc
variables: age at diagnosis of type 2 diabetes and time since diagnosis.
Furthermore, as there is evidence that diabetic dyslipidemia is qualitatively
different from dyslipidemia in the general population, total and HDL choles-
terol are included instead of LDL cholesterol. The complete model incorpo-
rates age at diagnosis of diabetes, diabetes duration, sex, smoking status, A1C
values, systolic blood pressure, and the total and/or HDL cholesterol ratio
(19). We plotted receiver operating characteristic (ROC) curves and the area
under the curve (AUC) was analyzed to study the value of the UKPDS CHD
risk engine for the prediction of carotid atherosclerosis (upper vs. lower two
tertiles of IMT). Calculations were performed using online provided software
(http//:www.dtu.ox.ac.uk). Intertertile cutoff points of IMT were 0.82 mm
(n  52), 0.82–0.94 mm (n  52), and 0.94 mm (n  52). Values for the AUC
as obtained by the UKPDS risk engine were compared with the AUC after
additional inclusion of AER and urinary adiponectin. Statistical comparisons
of the AUC ROC curves were performed using “roccomp” command provided
by the statistical software Stata/SE 8.2 for Windows (Stata Corporation,
College Station, TX). P  0.05 was considered to be statistically signiﬁcant.
RESULTS
Immunohistochemistry of adiponectin in human kid-
neys and determination of urinary adiponectin iso-
forms by Western blot. A strong staining for adiponectin
was detected on the endothelium of intrarenal arteries/
arterioles and on the endothelial surface of glomerular and
peritubular capillaries in all nondiabetic kidneys, and
representive ﬁndings are shown in Fig. 1A. In patients with
early diabetic nephropathy, the homogeneous glomerular
staining pattern of adiponectin was markedly decreased,
whereas adiponectin staining in intrarenal arteries/arterioles
remained unchanged (Fig. 1B). In type 2 diabetic kidney
biopsies, adiponectin was found in tubular casts, indicating
urinary excretion of the protein (Fig. 1C). In patients at
advanced stages of diabetic nephropathy with overt glomer-
ulosclerosis, glomerular staining for adiponectin was almost
completely lost (not shown).
Next, we studied whether adiponectin is speciﬁcally
detectable in urine of patients with diabetic nephropathy
and either current normoalbuminuria or microalbuminuria
and healthy control subjects and whether different iso-
forms of adiponectin are present in these samples. In
Western blot analyses of urine samples from patients with
diabetic nephropathy, the strongest signals were found at
75 kDa, most likely representing the low–molecular
weight adiponectin trimer (68 kDa). An additional signal at
25 kDa represents the adiponectin monomer (28 kDa)
(Fig. 1D) as previously shown for serum adiponectin (17).
In healthy control subjects, antigens representing adi-
ponectin dimers (56 kDa) and monomers were found;
however, overall intensity of these signals was much lower
compared with the diabetic patients studied (Fig. 1D).
Association of serum and urinary adiponectin levels
with cardiovascular risk factors. Characteristics of
control subjects and patients with type 2 diabetes and
bivariate analyses of associations between different vari-
ables and serum or urinary adiponectin are shown in Table
1. Serum adiponectin was signiﬁcantly lower and urinary
adiponectin levels signiﬁcantly higher in patients with type
2 diabetes than in control subjects (mean serum adiponec-
tin: 7.0  4.9 vs. 10.3  6.6 g/ml, P  0.033; mean urinary
adiponectin: 7.68  14.26 vs. 2.91  3.85 g/g creatinine,
P  0.008; Fig. 1E). Type 2 diabetic patients were more
often men, nonsmokers, and had higher age, BMI and
WHR compared with control subjects. As would be ex-
pected, type 2 diabetes was associated with signiﬁcantly
increased values of traditional cardiovascular risk factors,
such as LDL, triglycerides, systolic and diastolic blood
pressure, MAP, FPG, A1C, and hsCRP values (Table 1).
Kidney function was not signiﬁcantly different between
the two groups (type 2 diabetes, creatinine clearance:
109.6  40.7 vs. control subjects: 119.3  41.2 ml/min, P 
0.146), whereas serum cystatin C levels and levels of
albuminuria were signiﬁcantly higher in patients with type
2 diabetes than in control subjects, reﬂecting the early
functional alterations in diabetic nephropathy (mean cys-
tatin C: 0.79  0.31 vs. 0.57  0.13 mg/l, P  0.001; median
AER: 43.9 [21.5–103.1] vs. 10 mg/24 h, P  0.001; Table
1). Bivariate correlations showed signiﬁcant associations
between serum adiponectin and sex, age, WHR, HDL,
triglycerides, FPG, creatinine clearance, and hsCRP in
patients with type 2 diabetes. For urinary adiponectin,
there were no signiﬁcant correlations with components of
the metabolic syndrome like blood lipids or WHR, yet
there were signiﬁcant associations with increased age,
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itors or angiotensin receptor blockers (Table 1).
Twenty-one (13.5%) of the participants with type 2
diabetes were found to have increased urinary adiponectin
but no current albuminuria (Table 2, group 2). This sub-
group of patients did not differ signiﬁcantly from patients
without adiponectinuria (group 1) or current albuminuria
(group 3) with respect to age, glycemic control, and renal
function (Table 2). However, individuals in this group had
signiﬁcantly increased IMT compared with patients with-
out adiponectinuria (0.95  0.10 vs. 0.84  0.14 mm; P 
0.001) and patients with current albuminuria (0.95  0.10
vs. 0.89  0.15 mm; P  0.05), although the latter had
longer diabetes duration (13.6 [7.0–18.6] vs. 9.5 [5.8–17.3]
years: P  0.05) and increased FPG levels (8.67  2.97 vs.
6.94  2.67 mmol/l; P  0.01) (Table 2).
Associations of carotid atherosclerosis with urinary
and serum adiponectin and other CVD risk factors in
patients with type 2 diabetes. In bivariate correlation
analysis IMT was signiﬁcantly and positively associated
with urinary adiponectin (r  0.479, P  0.001) and
negatively associated with serum adiponectin levels (r 
0.202, P  0.017). Among other cardiovascular risk
factors, age (r  0.277, P  0.001), diabetes duration (r 
0.227, P  0.007), systolic blood pressure (r  0.171, P 
0.048), and LDL cholesterol (r  0.212, P  0.012) were
signiﬁcantly associated with IMT.
In multivariable linear regression analyses with IMT as
dependent variable, age (0.239, P  0.012), LDL
cholesterol (0.231, P  0.009), and diabetes duration
(0.197, P  0.026) were independently associated with
the extent of carotid atherosclerosis (Table 3). Urinary
adiponectin had the strongest association with IMT in this
model (0.360, P  0.001). We performed subgroup
analyses investigating a potential linear relationship be-
tween urinary adiponectin and IMT, and patients were
divided into quartiles of increasing urinary adiponectin. A
stepwise increase in urinary adiponectin was associated with
increased IMT (urinary adiponectin 1.05 g/g creatinine:
IMT mean [95% CI] 0.79 (0.75–0.83) mm; urinary adiponectin
1.05–1.89 g/g creatinine: IMT 0.85 (0.80–0.91) mm; urinary
adiponectin 1.90–7.20 g/g creatinine: IMT 0.89 (0.85–0.93)
FIG. 1. Adiponectin in human kidneys and urinary adiponectin excretion. Immunohistochemical analyses (ABC-POD method) of human kidney tissues
for adiponectin. A: Nondiabetic kidneys demonstrate strong endothelial adiponectin staining lining the glomerular and intertubular capillaries as well
as intrarenal arteries/arterioles (inserted panel). B: In patients with early diabetic nephropathy, adiponectin staining was considerably decreased in
glomerular capillaries, showing an inhomogeneous, segmental pattern. However, adiponectin was still present at the endothelial surface of intrarenal
arteries/arterioles (arrow). C: Positive adiponectin staining of tubular casts (arrowheads) in patients with diabetic nephropathy. D: Identiﬁcation of
adiponectin in urine. Urine from healthy individuals (Cont.), type 2 diabetic patients with normoalbuminuria (Norm.), and with microalbuminuria
(Alb.) was analyzed by Western blotting and representive ﬁndings are presented. In type 2 diabetic patients, bands were found running at 75 kDa,
most likely representing the adiponectin trimer (68 kDa). An additional weak band running at 25 kDa represents the adiponectin monomer (28 kDa).
In healthy control subjects, only adiponectin dimers (56 kDa) and monomers were found, and signal intensity was clearly decreased compared with the
diabetic patients studied. E: Dots represent individual urinary adiponectin levels in 156 patients with type 2 diabetes and 40 healthy control subjects.
Mean urinary adiponectin (SE) was signiﬁcantly higher in patients with type 2 diabetes compared with control subjects (P  0.008; gray bars). (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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(0.95–1.02) mm; P  0.001 by ANOVA; Fig. 2).
Predictive value of urinary adiponectin in compari-
son with urinary albumin for extent of carotid
atherosclerosis. We performed ROC analyses in models
including traditional cardiovascular risk factors adding
AER and urinary adiponectin levels to quantify their power
for the prediction of carotid IMT (upper vs. lower two
tertiles) in patients with type 2 diabetes. Carotid IMT as
well as the UKPDS CHD risk engine have previously been
shown to predict CVD risk in patients with type 2 diabetes
(19); in this study, the UKPDS CHD risk engine score and
IMT were signiﬁcantly correlated (r  0.509, P  0.001).
Therefore, the risk factors represented in the UKPDS CHD
risk engine (age at diabetes diagnosis, diabetes duration,
sex, smoking status, systolic blood pressure, A1C, and total
and HDL cholesterol) were chosen in a basis model for ROC
analysis. The UKPDS CHD risk engine factors reached an
AUC of 0.700 (95% CI 0.607–0.792, Fig. 3). Although urinary
albumin levels were signiﬁcantly associated with IMT in
bivariate analysis (r  0.202, P  0.010), further addition of
AER to the basis model did not signiﬁcantly alter the predic-
tive value for carotid IMT (AUC 0.702 [95% CI 0.610–0.795],
Fig. 3). Inclusion of urinary adiponectin added signiﬁcant
predictive value for prediction of IMT compared with the
basis model of the UKPDS CHD risk engine factors (AUC
0.800 [95% CI 0.724–0.872], P  0.007, Fig. 3).
DISCUSSION
This is the ﬁrst study evaluating urinary adiponectin as a
novel marker for vascular damage. The results of this study
imply that urinary adiponectin may emerge as a pathophysi-
ologically plausible and valuable marker for prevalent micro-
and macrovascular disease in type 2 diabetes.
The American guidelines recommend an ofﬁce-based
assessment as the initial step in predicting CVD risk in
primary prevention utilizing multifactorial statistical mod-
els (20). However, a certain proportion of patients will be
TABLE 2
Carotid IMT and characteristics of type 2 diabetic patients with and without adiponectinuria and albuminuria
12 3
Adiponectinuria () Adiponectinuria (	)
Albuminuria (	) Albuminuria () Albuminuria ()
n 43 21 92
Age (years) 60.8  8.9 61.4  7.1 60.7  7.0
Sex (male) 33 (76.7) 14 (66.7) 71 (77.2)
BMI (kg/m²) 32.3  5.0 32.7  6.6 33.6  6.4
FPG (mmol/l) 7.08  1.55 6.94  2.67 8.67  2.97*†
A1C (%) 6.9  0.8 7.2  1.6 7.4  1.2†
Creatinine clearance (ml/min) 111.5  46.2 109.1  29.5 107.9  41.0
Serum adiponectin (g/ml) 10.6  7.4 11.4  6.1 10.0  6.7
Duration of diabetes (years) 10.0 (5.0–13.0) 9.5 (5.8–17.3) 13.6 (7.0–18.6)†§
Carotid IMT (mm) 0.84  0.14 0.95  0.10 0.89  0.15†§
Data are means  SD, n (%), or median (interquartile range). Adiponectinuria is deﬁned as adiponectin excretion mean 	 2 SD (95th
percentile) of control urinary adiponectin excretion. Albuminuria is deﬁned as AER 30 mg/24 h. *P  0.01 for group 3 group 2; †P  0.05
for group 3 vs. group 1 (by independent t test or Mann-Whitney U test); §P  0.05; P  0.001 for group 2 vs. group 1.
TABLE 3
Independent predictors of IMT in patients with type 2 diabetes
Common carotid artery
IMT
 tP
Age (years) 0.239 2.562 0.012†
Sex (male) 0.118 1.114 0.268
WHR 0.142 1.274 0.206
HDL cholesterol (mmol/l) 0.239 1.497 0.138
LDL cholesterol (mmol/l) 0.231 2.649 0.009*
hsCRP (mg/l)† 0.034 0.393 0.696
A1C (%)† 0.089 1.031 0.305
AER (mg/24h)† 0.034 0.385 0.701
Current smoker (yes) 0.107 1.292 0.200
MAP, 24 h (mmHG) 0.104 1.219 0.226
Diabetes duration (years)† 0.197 2.269 0.026‡
Serum adiponectin (g/ml)† 0.128 1.362 0.177
Urinary adiponectin (g/g
creatinine)† 0.360 4.005 0.001§
r 0.665
r² 0.442
*P  0.01; †log-transformed variables; ‡P  0.05; §P  0.001.
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FIG. 2. Associations between urinary adiponectin levels and carotid
atherosclerosis in type 2 diabetes. A stepwise increase in urinary
adiponectin levels was associated with a signiﬁcant increase in IMT
(ANOVA: P < 0.001). Compared with patients in the lowest urinary
adiponectin quartile (<1.05 g/g creatinine), those with urinary adi-
ponectin excretion levels 1.05–1.89, 1.90–7.20, and >7.20 g/g creati-
nine had a signiﬁcantly increased extent of carotid IMT (all P < 0.02).
Comparisons between two sets of patients were performed by indepen-
dent t test. The central box represents the means  SE.
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CVD risk has particularly been underestimated in patients
with diabetes (21). Apart from albuminuria, atherogenic
dyslipidemia and to a lesser extent long-term glucose
control (that are included in the UKPDS risk engine),
novel biochemical risk markers were found to be of minor
importance for the overall prediction of CVD risk (2,6,7).
In this study, urinary adiponectin was superior to AER
in the prediction of increased IMT. Measurement of uri-
nary albumin excretion is currently utilized as a screening
test for the presence of diabetes-related kidney disease.
Furthermore, microalbuminuria is a marker of endothelial
dysfunction and predicts CVD in patients with type 2
diabetes (22,23). However, risk prediction by assessment
of urinary albumin levels reveals some important limita-
tions. A diabetes duration of 6 years may precede the
ﬁrst appearance of urinary albumin (24), and vascular
changes start long before the ﬁrst appearance of albumin
in urine and even before the diagnosis of diabetes (25,26).
Hence, closing this diagnostic gap is highly desired. In this
study, 13.5% of the type 2 diabetic patients were shown to
have a signiﬁcant adiponectinuria without current albu-
minuria. Despite similar age and glycemic control, this
subgroup of patients had a signiﬁcantly increased IMT
compared with participants without adiponectinuria or
current albuminuria (Table 2). In accordance with the
hypothesis, this implies that adiponectinuria could be an
early marker of endothelial damage on a prealbuminuric
level and that urinary adiponectin has the potential to
exceed the predictive value of urinary albumin for CVD
risk evaluation. However, although Table 2 shows signiﬁ-
cant differences between groups 2 and 3, the subgroup of
patients with adiponectinuria only (group 2) is small and
differences between the two groups will have to be studied
in larger cohorts. One possible explanation for the supe-
riority of urinary adiponectin compared with urinary albu-
min for prediction of increased IMT in this study could be
originated from previously published experimental and
clinical data. The prevalence of microalbuminuria in pa-
tients with type 2 diabetes is estimated at about 20%, and
about 30% in those subjects 55 years of age (27). Hence,
it appears that applicability of microalbuminuria for CVD
risk evaluation in type 2 diabetes per se is limited. More-
over, in large prospective cohort studies, the increased
risk for CVD started from urinary albumin levels well
below the cutoff for micoalbuminuria (25), and, thus, a
considerable percentage of high-risk patients will be
missed by screening for albuminuria utilizing current cut
off values. This has recently been supported by data in the
Finnish Diabetic Nephropathy (FinnDiane) Study, in
which a signiﬁcant number of type 1 diabetic patients at
high risk for premature death had normoalbuminuria (28).
The association between IMT and urinary adiponectin
shown here was independent of circulating adiponectin
levels. Moreover, urinary adiponectin levels did not signif-
icantly correlate with most of the traditional cardiovascu-
lar risk factors in bivariate analyses. This is an
advantageous precondition to achieve signiﬁcant addi-
tional value in risk prediction models. Although serum
adiponectin is strongly associated with the components of
the metabolic syndrome and closely linked to metabolic
risk factors like WHR, HDL cholesterol, and triglycerides,
urinary adiponectin seems to indicate vascular damage
and is therefore associated with older age and duration of
type 2 diabetes in this study.
The ﬁnding of extensive staining for adiponectin in
control kidneys, lining glomerular capillaries, and intrare-
nal arterioles was somehow unexpected, because in ro-
dents, adiponectin accumulation could only be detected in
injured vessels (29). Although histological examination of
tumor distant regions from resected kidney tissue, serving
as “healthy” control deserves cautious interpretation our
data indicate that binding of adiponectin to the glomerular
endothelium could be essential for kidney homeostasis.
This idea is further supported by two independent exper-
imental studies (13,30) in which adiponectin-deﬁcient
(Adip
/) mice treated with adiponectin showed a reduc-
tion of albuminuria, improvement of podocyte function,
and decreased urinary and glomerular markers of oxidant
stress. Thus, we speculate that the ubiquitous distribution
of adiponectin in nondiabetic glomerular capillaries in this
study and its subsequently increasing appearance in urine,
associated with loss of glomerular adiponectin in diabetic
nephropathy, might reﬂect earlier vascular damage than
the vascular leakage detected by albuminuria. On the
other hand, adiponectin was still present at the endothelial
surface of intrarenal arterioles in patients with diabetic
nephropathy that may be because of different functions of
adiponectin in these tissues (13,29,30). The role of adi-
ponectin in the human glomerulum needs to be addressed
in future studies because its excretion could be a more
pathophysiological marker of vascular stress and may
precede the onset of microalbuminuria and renal failure in
type 2 diabetes. Consistent with this hypothesis, we found
a signiﬁcant lower accumulation of adiponectin in glomer-
ular capillaries of patients with type 2 diabetes. This could
reﬂect an increased urinary loss of the adipokine and
might be explained by damage to the glomerular capillary
wall resulting in a signiﬁcant loss of endothelial binding
sites for adiponectin.
We recognize the limitations of the present study. The
cross-sectional design of our study warrants cautious
interpretation of the results, and further investigations in
large prospective trials with deﬁned CVD end points are
necessary to substantiate these ﬁndings. As all patients of
our study were selected by a previous history of mi-
croalbuminuria, future studies will have to address
whether the proposed association between urinary adi-
1.0 .8 .5 .3 0.0
1.0
.8
.5
.3
0.0
S
e
n
s
i
t
i
v
i
t
y
1- Specifity
FIG. 3. ROC curves of the UKPDS risk engine, albuminuria and urinary
adiponectin excretion, and predictive values for the extent of carotid
atherosclerosis. Prediction of carotid atherosclerosis extent was based
on discrimination between subjects with low or moderate (lower two
tertiles of common carotid artery IMT) and severe (upper IMT tertile)
carotid wall irregularities. The AUC for the UKPDS CHD risk engine
was 0.700 (95% CI 0.607–0.792); bold black line, basis model. Further
addition of the AER to the basis model did not signiﬁcantly alter the
predictive value for IMT (AUC 0.702 [95% CI 0.610–0.795]; dashed
line). On the other hand, inclusion of urinary adiponectin added
signiﬁcant value for the prediction of IMT compared with the basis
model of the UKPDS CHD risk engine factors (AUC 0.800; gray line).
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at advanced stages of diabetic nephropathy, as well as in
nonalbuminuric diabetic patients. Conclusions can only be
drawn for the high-risk group of type 2 diabetic patients in
this study. Moreover, because the number of histological
samples examined in this study is low, additional studies
are clearly needed to further elucidate the distribution
pattern of glomerular adiponectin in different renal pathol-
ogies to substantiate the potential role of adiponectin for
glomerular homeostasis in humans.
In conclusion, measurement of urinary adiponectin may
emerge as a novel and easy-to-obtain method for the
clinical assessment of vascular stress and CVD risk in type
2 diabetes that needs to be validated in larger prospective
studies and different samples including diabetic patients
without a history of microalbuminuria.
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